Tag Archives: Eli Lilly and Company

Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial

INDIANAPOLIS, Nov. 23, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs

Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over one year INDIANAPOLIS, June 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and

Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)

Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate – the current standard of care – and adalimumab (Humira®)* INDIANAPOLIS, June 9, 2016 /PRNewswire/ — Eli Lilly

Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016)

Lilly immunology portfolio to be featured in 16 presentations INDIANAPOLIS, June 7, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib’s phase

New Data Show Lilly’s Once-Weekly Trulicity® (dulaglutide) Solution for Injection is Effective as Add-on Treatment to Sulfonylurea

Trulicity 1.5 mg Demonstrates Superior Efficacy in AWARD-8 Trial INDIANAPOLIS, Dec. 1, 2015 /PRNewswire/ — New data from a completed Phase 3 trial show Trulicity® (dulaglutide) solution for injection 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone

Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis

— Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab — Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab — Detailed results from pivotal phase 3 study

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate

– Compared to methotrexate, baricitinib as monotherapy or in combination with methotrexate demonstrated improvements in all ACR components as early as week 1 and maintained through 52 weeks – Both baricitinib regimens were superior to methotrexate monotherapy in inducing clinical

Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis

INDIANAPOLIS, Sept. 29, 2015 / PRNewswire — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for

EASD: Additional Evidence Showed ABASAGLAR® (insulin glargine) Provided Safety and Efficacy Similar to Lantus®

Secondary analyses evaluated ABASAGLAR® in patients previously treated with Lantus® insulin glargine STOCKHOLM, Sept. 15, 2015 / PRNewswire — Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR® (insulin glargine), Eli Lilly and Company and Boehringer Ingelheim’s biosimilar

Lilly Announces Agreement to Acquire Novartis Animal Health

- $5.4 billion deal creates world’s second-largest animal health company. - Combination will increase Elanco’s product portfolio, expand its global commercial presence, and enhance manufacturing and R&D capabilities. - Combined organization is committed to leading the animal health industry in